Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation

References

• Trulock EP Christie JD Edwards LB Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007 J Heart Lung Transplant 2007 26 8 782 795 17692782
   PubMed Web of Science ®Google Scholar
• Taylor DO Edwards LB Boucek MM Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007 J Heart Lung Transplant 2007 26 8 769 781 17692781
   PubMed Web of Science ®Google Scholar
• Boehler A Estenne M Post-transplant bronchiolitis obliterans Eur Respir J 2003 22 6 1007 1018 14680094
   PubMed Web of Science ®Google Scholar
• Estenne M Maurer JR Boehler A Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria J Heart Lung Transplant 2002 21 3 297 310 11897517
   PubMed Web of Science ®Google Scholar
• Hayes DJr A review of bronchiolitis obliterans syndrome and therapeutic strategies J Cardiothorac Surg 2011 6 92 1 9 21208441
   PubMed Web of Science ®Google Scholar
• Hayes DJr Mansour HM Kirkby S Phillips AB Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection Transpl Infect Dis 2012 1 3
   Web of Science ®Google Scholar
• Yousem SA Berry GJ Cagle PT Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group J Heart Lung Transplant 1996 15 1 Pt 1 1 15 8820078
   PubMed Web of Science ®Google Scholar
• Halloran PF Homik J Goes N The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes Transplant Proc 1997 29 1–2 79 81 9123164
   PubMed Web of Science ®Google Scholar
• Knoop C Haverich A Fischer S Immunosuppressive therapy after human lung transplantation Eur Respir J 2004 23 1 159 171 14738248
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA Patel J Furukawa H Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients J Heart Lung Transplant 4 2006 25 4 434 439 16563974
   PubMed Web of Science ®Google Scholar
• Briffa N Morris RE New immunosuppressive regimens in lung transplantation Eur Respir J 1997 10 11 2630 2637 9426106
   PubMed Web of Science ®Google Scholar
• van den Berg JW Postma DS Koeter GH van der Bij W New immunosuppressive drugs and lung transplantation: last or least? Thorax 1999 54 6 550 553 10335012
   PubMed Web of Science ®Google Scholar
• Wiederrecht G Lam E Hung S Martin M Sigal N The mechanism of action of FK-506 and cyclosporin A Ann N Y Acad Sci 1993 696 9 19 7509138
   PubMed Web of Science ®Google Scholar
• Siekierka JJ Sigal NH FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond Curr Opin Immunol 1992 4 5 548 552 1384551
   PubMed Web of Science ®Google Scholar
• Rondeau E Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin Nephrologie 1992 13 3 137 1379348
   PubMedGoogle Scholar
• Kino T Hatanaka H Hashimoto M FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics J Antibiot (Tokyo) 1987 40 9 1249 1255 2445721
   PubMed Web of Science ®Google Scholar
• Keicho N Sawada S Kitamura K Yotsumoto H Takaku F Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937 Cell Immunol 1991 132 2 285 294 1703047
   PubMed Web of Science ®Google Scholar
• Sakr MF McClain CJ Gavaler JS Zetti GM Starzl TE Van Thiel DH FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion J Hepatol 1993 17 3 301 307 7686193
   PubMed Web of Science ®Google Scholar
• Clardy J The chemistry of signal transduction Proc Natl Acad Sci U S A 1995 92 1 56 61 7529414
   PubMed Web of Science ®Google Scholar
• Almawi WY Melemedjian OK Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A Nephrology, Dialysis, Transplantation 2000 15 12 1916 1918
   Web of Science ®Google Scholar
• Borro J Bravo C Solé A Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome Transplant Proc 2007 39 7 2416 2419 17889206
   PubMed Web of Science ®Google Scholar
• Canadas O Guerrero R Garcia-Canero R Orellana G Menendez M Casals C Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity Biochemistry 2004 43 30 9926 9938 15274647
   PubMed Web of Science ®Google Scholar
• Taketomo C Hodding J Kraus D Pediatric Dosage Handbook 16th ed Hudson, OH American Pharmacists Association 2009 1173
   Google Scholar
• Kur F Reichenspurner H Meiser BM Tacrolimus (FK506) as primary immunosuppressant after lung transplantation Thorac Cardiovasc Surg 1999 47 3 174 178 10443520
   PubMed Web of Science ®Google Scholar
• Hayes DJr Zwischenberger JB Mansour HM Aerosolized tacrolimus in a lung transplant recipient Transplant Proc 2010 42 9 3876 3879 21094875
   PubMed Web of Science ®Google Scholar
• Park CW Hayes DJr Mansour HM Pulmonary inhalation aerosols for targeted antibiotics drug delivery. invited paper European Pharmaceutical Review 2011 16 1 32 36
   Google Scholar
• Hickey AJ Mansour HM Chapter 5: delivery of drugs by the pulmonary route Florence AT Siepmann J Modern Pharmaceutics 5th ed New York Taylor and Francis, Inc 2009 2 191 219
   Google Scholar
• Patton JS Byron PR Inhaling medicines: delivering drugs to the body through the lungs Nat Rev Drug Discov 2007 6 1 67 74 17195033
   PubMed Web of Science ®Google Scholar
• Iacono AT Corcoran TE Griffith BP Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans Eur Respir J 2004 23 3 384 390 15065826
   PubMed Web of Science ®Google Scholar
• Niven R Toward managing chronic rejection after lung transplant: the fate and effects of inhaled cyclosporine in a complex environment Adv Drug Deliv Rev 2011 63 1–2 88 109 20950661
   PubMed Web of Science ®Google Scholar
• Corcoran TE Inhaled delivery of aerosolized cyclosporine Adv Drug Deliv Rev 2006 58 9–10 1119 1127 16997418
   PubMed Web of Science ®Google Scholar
• Mansour H Wang DS Chen CS Zografi G Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol Langmuir 2001 17 21 6622 6632
   Web of Science ®Google Scholar
• Morrow MR Temple S Stewart J Keough KM Comparison of DPPC and DPPG environments in pulmonary surfactant models Biophys J 2007 93 1 164 175 17434940
   PubMed Web of Science ®Google Scholar
• Mansour HM Zografi G Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface Langmuir 2007 23 7 3809 3819 17323986
   PubMed Web of Science ®Google Scholar
• Mansour HM Damodaran S Zografi G Characterization of the in situ structural and interfacial properties of the cationic hydrophobic heteropolypeptide, KL4, in lung surfactant bilayer and monolayer models at the air-water interface: implications for pulmonary surfactant delivery Mol Pharm 2008 5 5 681 695 18630875
   PubMed Web of Science ®Google Scholar
• Goerke J Pulmonary surfactant: functions and molecular composition Biochim Biophys Acta 1998 1408 2–3 79 89 9813251
   PubMed Web of Science ®Google Scholar
• Veldhuizen R Nag K Orgeig S Possmayer F The role of lipids in pulmonary surfactant Biochim Biophys Acta 1998 1408 2–3 90 108 9813256
   PubMed Web of Science ®Google Scholar
• Postle AD Heeley EL Wilton DC A comparison of the molecular species compositions of mammalian lung surfactant phospholipids Comp Biochem Physiol A Mol Integr Physiol 2001 129 1 65 73 11369534
   PubMed Web of Science ®Google Scholar
• Mansour HM Rhee YS Wu X Nanomedicine in pulmonary delivery Int J Nanomedicine 2009 4 299 319 20054434
   PubMed Web of Science ®Google Scholar
• Mansour HM Rhee YS Park CW DeLuca PP Lipid nanoparticulate drug delivery and nanomedicine Moghis A Lipids in Nanotechnology 1st ed Urbana, IL American Oil Chemists Society (AOCS) Press 2011 221 268
   Google Scholar
• Mansour HM Park CW Hayes DJr Nanoparticle lung delivery and inhalation aerosols for targeted pulmonary nanomedicine Kumar A Mansour HM Friedman A Blough E Nanomedicine in Drug Delivery London, UK CRC Press/Taylor Francis Inc 2013 In press
   Google Scholar
• Rhee YS Mansour HM Nanopharmaceuticals I: nanocarrier systems in drug delivery. Invited paper Int J Nanotechnol 2011 8 1–2 84 114
   Web of Science ®Google Scholar
• Wu X Mansour HM Nanopharmaceuticals II: application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine. Invited paper Int J Nanotechnol 2011 8 1–2 115 145
   Web of Science ®Google Scholar
• Hickey AJ Mansour HM Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols Rathbone MJ Hadgraft J Roberts MS Lane ME Modified-Release Drug Delivery Technology 2nd ed New York Informa Healthcare 2008 2 573 602
   Google Scholar
• Li X Mansour HM Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery AAPS PharmSciTech 2011 12 4 1420 1430 22038473
   PubMed Web of Science ®Google Scholar
• Meenach SA Vogt FG Anderson KW Hilt JZ McGarry RC Mansour HM Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols Int J Nanomedicine 2013 8 275 293 23355776
   PubMed Web of Science ®Google Scholar
• Canadas O Guerrero R Garcia-Canero R Orellana G Menendez M Casals C Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity Biochemistry 2004 43 30 9926 9938 15274647
   PubMed Web of Science ®Google Scholar
• Xu Z Mansour HM Mulder T McLean R Langridge J Hickey AJ Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate J Pharm Sci 2010 99 8 3415 3429 20222025
   PubMed Web of Science ®Google Scholar
• Mansour HM Xu Z Hickey AJ Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and D-mannitol carriers J Pharm Sci 2010 99 8 3430 3441 20229601
   PubMed Web of Science ®Google Scholar
• Park CW Rhee YS Vogt F Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex-vivo in respiratory drug delivery. Invited Paper Adv Drug Deliv Rev 2012 64 4 344 356 21920394
   PubMed Web of Science ®Google Scholar
• Hickey AJ Mansour HM Telko MJ Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics J Pharm Sci 2007 96 5 1282 1301 17455324
   PubMed Web of Science ®Google Scholar
• Mansour HM Zografi G The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions J Pharm Sci 2007 96 2 377 396 17080427
   PubMed Web of Science ®Google Scholar
• Xu Z Mansour HM Mulder T McLean R Langridge J Hickey AJ Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate J Pharm Sci 2010 99 8 3398 3414 20198688
   PubMed Web of Science ®Google Scholar
• Willis L Hayes DJr Mansour HM Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery Lung 2012 190 3 251 262 22274758
   PubMed Web of Science ®Google Scholar
• Wu X Li X Mansour HM Surface analytical techniques in solid-state particle characterization: implications for predicting performance in dry powder inhalers. Invited paper KONA Powder and Particle Journal 2010 28 3 19
   Google Scholar
• Xu Z Mansour HM Hickey AJ Particle interactions in dry powder inhaler unit processes J Adhes Sci Technol 2011 25 4–5 451 482
   Web of Science ®Google Scholar
• Alves GP Santana MHA Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties Powder Technol 2004 145 139 148
   Web of Science ®Google Scholar
• Andya JD Maa YF Costantino HR The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody Pharm Res 1999 16 3 350 358 10213364
   PubMed Web of Science ®Google Scholar
• Sollohub K Cal K Spray drying technique: II. Current applications in pharmaceutical technology J Pharm Sci 2010 99 2 587 597 19862804
   PubMed Web of Science ®Google Scholar
• Yu J Chien YW Pulmonary drug delivery: physiologic and mechanistic aspects Crit Rev Ther Drug Carrier Syst 1997 14 4 395 453 9450176
   PubMed Web of Science ®Google Scholar
• Schulz H Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies Holger Schulz Pharm Sci Technol Today 1998 1 8 326 344
   Google Scholar
• Master L Spray Drying Handbook 5th ed New York Longman 1991
   Google Scholar
• Li DX Oh YK Lim SJ Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique Int J Pharm 2008 355 1–2 277 284 18243606
   PubMed Web of Science ®Google Scholar
• Chew NY Chan HK Use of solid corrugated particles to enhance powder aerosol performance Pharm Res 2001 18 11 1570 1577 11758765
   PubMed Web of Science ®Google Scholar
• Chew NY Tang P Chan HK Raper JA How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 2005 22 1 148 152 15771241
   PubMed Web of Science ®Google Scholar
• Maa YF Costantino HR Nguyen PA Hsu CC The effect of operating and formulation variables on the morphology of spray-dried protein particles Pharm Dev Technol 1997 2 3 213 223 9552449
   PubMedGoogle Scholar